Developing a PTEN-ERG Signature to Improve Molecular Risk Stratification in Prostate Cancer
Abstract
Based on previous work and our own preliminary data, it is clear that there exist distinctive molecular correlates of PTEN loss in the context of ETS-negative versus ETS-positive human prostate cancers and that these may drive prognosis following PTEN loss. Ultimately, elucidation of the molecular underpinnings of PTEN-ERG crosstalk holds promise for clarifying the mechanisms underlying the aggressive behavior seen in ERG-negative/PTEN-negative tumors, and may enable rational design of more effective therapeutic strategies and prognosticators for this subset of patients. We propose to test two hypotheses generated by our preliminary data: 1) PTEN loss in the absence of ETS gene expression is associated with an increased proliferative rate and a significantly increased risk of metastasis and death; and 2) ETS expression interacts with PTEN loss to modulate the transcriptional output from key oncogenic transcription factors such as MYC. Here we report on the initial studies performed for this award.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2017
- Accession Number
- AD1046109
Entities
People
- Tamara L Lotan